Proprietary AI analyst is now available

Co-Diagnostics Valuation Multiples

Discover Co-Diagnostics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Iconovo, Milton Essex, Clinical Laserthermia, Scandinavian Medical and more.

Co-Diagnostics Overview

About Co-Diagnostics

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.


Founded

2013

HQ

United States

Employees

115

Financials (LTM)

Revenue: $622K
Net Income: ($47M)

EV

$5M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Co-Diagnostics Financials

Co-Diagnostics reported last 12-month revenue of $622K.

In the same LTM period, Co-Diagnostics generated had net loss of ($47M).

Revenue (LTM)


Co-Diagnostics P&L

In the most recent fiscal year, Co-Diagnostics reported revenue of $622K and EBITDA of ($30M).

Co-Diagnostics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).

See analyst estimates for Co-Diagnostics
LTMLast FY202320242025202620272028
Revenue$622K$622K$7M$4M$622K
Gross Profit-$400K$3M$3M$400K
Gross Margin-64%39%74%64%
EBITDA-($30M)($41M)($39M)($30M)
EBITDA Margin-(4848%)(609%)(989%)(4848%)
EBIT Margin-(5026%)(627%)(1024%)(5026%)
Net Profit($47M)($47M)($35M)($38M)($47M)
Net Margin(7534%)(7534%)(519%)(961%)(7534%)

Financial data powered by Morningstar, Inc.

Co-Diagnostics Stock Performance

Co-Diagnostics has current market cap of $11M, and enterprise value of $5M.

Market Cap Evolution


Co-Diagnostics' stock price is $3.12.

Co-Diagnostics share price decreased by 63.4% in the last 30 days.

Co-Diagnostics has an EPS (earnings per share) of $-12.73.

See more trading valuation data for Co-Diagnostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5M$11M-7.4%-63.4%67.7%-$-12.73

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Co-Diagnostics Valuation Multiples

Co-Diagnostics trades at 8.5x EV/Revenue multiple, and (0.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Co-Diagnostics

EV / Revenue (LTM)


Co-Diagnostics Financial Valuation Multiples

As of June 23, 2026, Co-Diagnostics has market cap of $11M and EV of $5M.

Co-Diagnostics has a P/E ratio of (0.2x).

LTMLast FY202320242025202620272028
EV/Revenue8.5x8.5x0.8x1.4x8.5x
EV/EBITDA-(0.2x)(0.1x)(0.1x)(0.2x)
EV/EBIT-(0.2x)(0.1x)(0.1x)(0.2x)
EV/Gross Profit-13.2x2.0x1.8x13.2x
P/E(0.2x)(0.2x)(0.3x)(0.3x)(0.2x)
EV/FCF-(0.2x)(0.2x)(0.2x)(0.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Co-Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Co-Diagnostics Margins & Growth Rates

In the most recent fiscal year, Co-Diagnostics reported gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).

See estimated margins and future growth rates for Co-Diagnostics

Co-Diagnostics Margins

Last FY20242025202720282029
Gross Margin64%74%64%
EBITDA Margin(4848%)(989%)(4848%)
EBIT Margin(5026%)(1024%)(5026%)
Net Margin(7534%)(961%)(7534%)
FCF Margin(4793%)(764%)(4793%)

Co-Diagnostics Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(43%)(84%)
Gross Profit Growth11%(86%)
EBITDA Growth(7%)(22%)
EBIT Growth(6%)(22%)
Net Profit Growth7%25%
FCF Growth28%(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Co-Diagnostics Operational KPIs

Co-Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Co-Diagnostics
Last FY202320242025202620272028
Revenue per Employee$0.0M---
Opex per Employee$0.3M---
S&M Expenses to Revenue383%101%115%383%
G&A Expenses to Revenue1455%210%413%1455%
R&D Expenses to Revenue3074%337%536%3074%
Opex to Revenue5090%665%1098%5090%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Co-Diagnostics Competitors

Co-Diagnostics competitors include Iconovo, Milton Essex, Clinical Laserthermia, Scandinavian Medical, Trinity Biotech, Renalytix, Jana Medical Company, Conneqt Health, Spineguard and Predict.

Most Co-Diagnostics public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Iconovo60.7x4.7x(2.0x)(2.1x)
Milton Essex546.4x-(133.6x)-
Clinical Laserthermia4.7x3.6x(3.1x)(3.3x)
Scandinavian Medical0.6x0.6x13.6x19.5x
Trinity Biotech3.3x-(6.8x)-
Renalytix3.5x3.5x(0.5x)-
Jana Medical Company0.8x-(2.1x)-
Conneqt Health4.7x5.0x(1.0x)-

This data is available for Pro users. Sign up to see all Co-Diagnostics competitors and their valuation data.

Start Free Trial

Acquisitions by Co-Diagnostics

Co-Diagnostics has acquired 3 companies to date.

Last acquisition by Co-Diagnostics was on December 23rd 2021. Co-Diagnostics acquired Idaho Molecular for $21M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Co-Diagnostics

Idaho Molecular
Advanced Conceptions
MEDCIS Pathlabs India Pvt. Ltd.
Description
Idaho Molecular is a Meridian-based biotechnology firm developing diagnostic devices for labs, hospitals, and research facilities. The company produces molecular testing platforms for infectious diseases and genetic analysis, enabling rapid data-driven decisions. Idaho Molecular's solutions integrate PCR technology and cloud-based reporting for clinical applications.
Advanced Conceptions is a medical device company specializing in diagnostic and therapeutic tools for reproductive health. Mountain View, California-based, it develops intrauterine devices and fertility assessment systems to improve conception rates and embryo selection.
MEDCIS Pathlabs India Pvt. Ltd. is a clinical investigation laboratory providing diagnostic services in pathology, biochemistry, microbiology, and histopathology across India. Hyderabad-based, the company integrates global diagnostic technologies to support physician decision-making with accurate test reports in multiple medical branches.
HQ CountryUnited StatesUnited StatesIndia
HQ City
Salt Lake City, UT
Salt Lake City, UT
Hyderabad
Deal Date23 Dec 202123 Dec 20215 Sep 2017
Valuation$21M$36Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Co-Diagnostics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Co-Diagnostics

Who are competitors of Co-Diagnostics?Co-Diagnostics main competitors include Iconovo, Milton Essex, Clinical Laserthermia, Scandinavian Medical, Trinity Biotech, Renalytix, Jana Medical Company, Conneqt Health, Spineguard, Predict.

See public comps similar to Co-Diagnostics

Lists including Co-Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial